<DOC>
<DOCNO>EP-0645376</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted 1-phenyl-oxazolidin-2-one derivatives, their preparation and their use as adhesion-receptor antagonists
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P1910	A61P4300	A61K31496	A61K3144	A61P700	A61P900	A61K3142	C07D26300	A61P4300	A61K31496	A61K31421	A61K31505	C07D41300	A61P910	A61P3500	A61K3142	A61K31421	A61P702	A61P2900	C07D41312	A61P1900	C07D26320	A61P2900	A61K3144	C07D26324	A61P3304	A61P3500	A61P908	A61K31505	A61P3300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	A61K	A61P	A61P	A61K	C07D	A61P	A61K	A61K	A61K	C07D	A61P	A61P	A61K	A61K	A61P	A61P	C07D	A61P	C07D	A61P	A61K	C07D	A61P	A61P	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P19	A61P43	A61K31	A61K31	A61P7	A61P9	A61K31	C07D263	A61P43	A61K31	A61K31	A61K31	C07D413	A61P9	A61P35	A61K31	A61K31	A61P7	A61P29	C07D413	A61P19	C07D263	A61P29	A61K31	C07D263	A61P33	A61P35	A61P9	A61K31	A61P33	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel oxazolidinone derivatives of the formula I 
<
IMAGE
>
  wherein   R
<
1
>
 is a phenyl radical which is unsubstituted or substituted once by CN, H2N-CH2-, A2N-CH2-, H2N-C(=NH)-, H2N-C(=NH)-NH-, H2N-C(=NH)-NH-CH2-, HO-NH-C(=NH)- or HO-NH-C(=NH)-NH-,   X is O, S, SO, SO2, -NH- or -NA-,   B is 
<
IMAGE
>
     A is alkyl having 1 to 6 C atoms,   R
<
2
>
 is H, A, Li, Na, K, NH4 or benzyl,   R
<
3
>
 is H or (CH2)n-COOR
<
2
>
,   E in each case independently of one another is CH or N,   Q is O, S or NH,   m is 1, 2 or 3 and   n is 0, 1, 2 or 3, and their physiologically acceptable salts inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, apoplexy, cardiac infarct, inflammations, arteriosclerosis, osteoporosis and tumours.
 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Oxazolidinone derivatives of the formula I


in which

R
1
is a phenyl radical which is monosubstituted by
H
2
N-CH
2
-, (A)
2
N-CH
2
-, H
2
N-C(=NH)-, H
2
N-C(=NH)-NH-,
H
2
N-C(=NH)-NH-CH
2
-, HO-NH-C(=NH)- or
HO-NH-C(=NH)-NH-,
X
is O,
B
is

A
is alkyl having from 1-6 C atoms,
R
2
is H, A, Li, Na, K, NH
4
 or benzyl,
R
3
is H or (CH
2
)
n
-COOR
2
,
E
is CH,
m
is 1, 2 or 3, and
n
is 0, 1, 2 or 3,

and physiologically harmless salts thereof.
Compounds according to Claim 1

(a) 3-p-Amidinophenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one;
(b) 3-p-Amidinophenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one; 
(c) 3-p-Aminomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one
sodium salt;
(d) 3-p-Guanidinomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one.
An enantiomeric compound of the formula I
according to Claim 1 or one of its salts.
Process for preparing compounds of the formula I
according to Claim 1, and also their salts, characterized

in that a compound of the formula II


in which

R
1
has the meaning given in Claim 1,

and

Z
is Cl, Br, I, OH or a reactive esterified OH group,

is reacted with a compound of the formula III

Y-B

in which

B
has the meanings given in Claim 1,

and

Y
is OH, SH, NH
2
, NAH or a salt-like radical which can
be derived from OH or SH,

or in that

a compound of the formula IV

R
1
-NH-CH
2
-CH(OH)-CH
2
-X-B

in which

R
1
, B and X have the meanings given in Claim 1, or one of
its reactive derivatives, is reacted with a reactive

derivative of carbonic acid,

or in that, in order to prepare a guanidino compound of
the formula I (R
1
 = a phenyl radical which is monosubstituted
by H
2
N-C(=NH)-NH-), an amino compound corresponding 
to the formula I, which compound, however,

contains an aminophenyl group in place of the radical R
1
,
is treated with an amidinating agent,

or in that a compound of the formula I is liberated from
one of its functional derivatives by treatment with a

solvolysing or hydrogenolysing agent,

and/or in that, in a compound of the formula I, one or
both of the radicals R
1
 and/or B is/are converted into
(an) other radical(s) R
1
 and/or B, and/or a compound of
the formula I is converted into one of its salts by

treatment with an acid or a base.
Process for producing pharmaceutical preparations,
characterized in that a compound of the formula I

according to Claim 1 and/or one of its physiologically
harmless salts is brought into a suitable dosage form

together with at least one solid, liquid or semiliquid
excipient or auxiliary substance.
Pharmaceutical preparation, characterized by a
content of at least one compound of the formula I according

to Claim 1 and/or one of its physiologically harmless
salts.
Use of compounds of the formula I according to
Claim 1, or of their physiologically harmless salts, for

producing a medicament.
Use of compounds of the formula I according to
Claim 1, or of their physiologically harmless salts, in

the control of thromboses, cardiac infarctions, stroke,
osteoporosis, arteriosclerosis, inflammations and/or

tumours.
</CLAIMS>
</TEXT>
</DOC>
